Compass Therapeutics, Inc. (NASDAQ: CMPX) reported Q4 EPS of ($0.11), $0.01 worse than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Compass Therapeutics, Inc. (CMPX) click here.